Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 12:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,484 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Demyelinating Diseases Clear all
Completed Not applicable Interventional

Lakeshore Examination of Activity and Disability Exercise Response Study

NCT02533882
View directory record Official record
Conditions
Multiple Sclerosis, Stroke
Interventions
Movement to Music, Adapted Yoga
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 9, 2026, 12:34 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Effects of Dalfampridine on Cognition in Multiple Sclerosis

NCT02006160
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dalfampridine, placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Sep 9, 2026, 12:34 AM EDT
Completed Not applicable Interventional Results available

Telehealth Pain Self-Management for Employed Adults

NCT04248725
View directory record Official record
Conditions
Chronic Pain, Brain Injuries, Traumatic, Multiple Sclerosis, Spinal Cord Injuries, Amputation
Interventions
E-TIPS
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 9, 2026, 12:34 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

NCT02284568
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Placebo, Laquinimod
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 9, 2026, 12:34 AM EDT
Terminated Phase 4 Interventional Results available

Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation

NCT02217982
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Simethicone, Loperamide, Peanut Butter
Drug · Other
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 9, 2026, 12:34 AM EDT
Active, not recruiting No phase listed Observational

Investigating the Impact of Sex Hormones in Multiple Sclerosis

NCT07081594
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Milap Sandhu
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 9, 2026, 12:34 AM EDT
Recruiting No phase listed Observational

The Myelin Disorders Biorepository Project

NCT03047369
View directory record Official record
Conditions
Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 9, 2026, 12:34 AM EDT
Completed No phase listed Observational

A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia

NCT07168694
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 9, 2026, 12:34 AM EDT
Terminated Phase 4 Interventional

The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis

NCT00151294
View directory record Official record
Conditions
Depression, Multiple Sclerosis
Interventions
escitalopram oxalate antidepressant
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2006 · Synced Sep 9, 2026, 12:34 AM EDT
Completed Not applicable Interventional

Physical Telerehabilitation in Multiple Sclerosis

NCT03230903
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Home telerehabilitation, Usual Care
Other
Lead sponsor
Columbia University
Other
Eligibility
22 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 9, 2026, 12:34 AM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

NCT07304154
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
Interventions
KITE-363, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Newport Beach, California • Palo Alto, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 9, 2026, 12:34 AM EDT
Completed Phase 4 Interventional

Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients

NCT01968902
View directory record Official record
Conditions
Muscle Spasticity, Multiple Sclerosis
Interventions
incabotulinumtoxinA, Placebo
Biological
Lead sponsor
Multiple Sclerosis Center of Northeastern New York
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Latham, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 9, 2026, 12:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study on Teriflunomide-exposed Pregnancies

NCT03198351
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide (HMR1726)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 9, 2026, 12:34 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT02283853
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Interferon β-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 9, 2026, 12:34 AM EDT
Completed Phase 2 Interventional Results available

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

NCT01116427
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
abatacept, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
20
States / cities
Phonix, Arizona • Berkeley, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 9, 2026, 12:34 AM EDT
Completed No phase listed Observational

Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies

NCT06459232
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 9, 2026, 12:34 AM EDT
Completed No phase listed Observational

Safety Study of GBS Following Menactra Meningococcal Vaccination

NCT00575653
View directory record Official record
Conditions
Guillain-Barre Syndrome
Interventions
Not listed
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
11 Years to 21 Years
Enrollment
6,000,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
6
States / cities
Wilmington, Delaware • Honolulu, Hawaii • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 9, 2026, 12:34 AM EDT
Completed Phase 3 Interventional Results available

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

NCT00930553
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
alemtuzumab
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
69
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 9, 2026, 12:34 AM EDT
Completed No phase listed Observational

Assessment of Patients With Multiple Sclerosis (MS)

NCT00001156
View directory record Official record
Conditions
Herpesviridae Infection, HTLV-I Infection, Multiple Sclerosis, Tropical Spastic Paraparesis, Vasculitis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1976 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 12:34 AM EDT
Completed No phase listed Observational Results available

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study

NCT04754542
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Aurora, Colorado • Kansas City, Kansas • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 9, 2026, 12:34 AM EDT
Terminated Phase 1Phase 2 Interventional

Cannabis for Spasticity in Multiple Sclerosis

NCT00260741
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Smoked Cannabis
Drug
Lead sponsor
Center for Medicinal Cannabis Research
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2007 · Synced Sep 9, 2026, 12:34 AM EDT
Not yet recruiting Not applicable Interventional

Comparison of Gait Metrics in Patients With Stroke, Traumatic Brain Injury, and Multiple Sclerosis

NCT07492602
View directory record Official record
Conditions
Stroke, Traumatic Brain Injury, Multiple Sclerosis
Interventions
Functional Electrical Stimulation, Normal care
Device
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 9, 2026, 12:34 AM EDT
Completed No phase listed Observational

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

NCT06897657
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 9, 2026, 12:34 AM EDT
Completed Not applicable Interventional

Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS

NCT02010554
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Brief Education, Motivational Interviewing-Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Kansas City, Missouri • West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Sep 9, 2026, 12:34 AM EDT